Aldeyra Therapeutics, Inc. (ALDX)
Health Care · ophthalmology / inflammation therapeutics (clinical-stage) · Nasdaq
Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on addressing regulatory feedback and securing capital for development and commercialization.
What Aldeyra Therapeutics, Inc. does
Aldeyra Therapeutics is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of reproxalap, its lead product candidate. The company is advancing reproxalap through regulatory processes, with plans to pursue FDA approval and commercialize it potentially alone or through strategic partnerships. Aldeyra operates in the pharmaceutical development space, targeting ophthalmologic and other therapeutic indications, though it has not yet generated significant product revenue.
Themes: ["ophthalmology","inflammation / immunology","clinical-stage biotech","FDA approval / regulatory pathway"]
Fundamentals
- Price$2.07 as of 2026-07-10 close
- Market cap$125M as of 2026-07-13
- 1-year return-56.9% as of 2026-07-10 close
- ROE-57.3% as of 2026-07-13
- Debt / equity0.36 as of 2026-07-13
- Beta1.19 as of 2026-07-13
Key risks (from latest filing)
["Reproxalap has not yet received FDA approval; the company faces regulatory uncertainty and must address FDA Complete Response Letter issues before resubmission","The company has incurred significant operating losses since inception and is dependent on external capital; failure to raise additional financing could force delays or termination of product development","Even if reproxalap achieves regulatory approval, successful commercialization is uncertain and depends on market acceptance, pricing, reimbursement, and competition from other treatments"]
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.